These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2856702)

  • 21. Moderate essential hypertension control: a double-blind crossover study between a serotonin antagonist and a post-synaptic alpha-blocker.
    Rosenthal J; Koehle W; Gruebel B; Fisher R
    J Hypertens Suppl; 1986 Apr; 4(1):S85-7. PubMed ID: 2871145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Demonstration of alpha-adrenoceptor antagonism by the 5HT2 antagonist, ketanserin (R49945), in sheep.
    Nelson MA; Coghlan JP; Denton DA; Mills EH; Spence CD; Whitworth JA; Scoggins BA
    Clin Exp Pharmacol Physiol; 1984; 11(6):597-604. PubMed ID: 6152610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.
    Van Nueten JM; Janssen PA; Van Beek J; Xhonneux R; Verbeuren TJ; Vanhoutte PM
    J Pharmacol Exp Ther; 1981 Jul; 218(1):217-30. PubMed ID: 6113280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension.
    Zabludowski JR; Zoccali C; Isles CG; Murray GD; Robertson JI; Inglis GC; Fraser R; Ball SG
    Br J Clin Pharmacol; 1984 Mar; 17(3):309-16. PubMed ID: 6712863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of ketanserin on blood pressure and heart rate during induction of anesthesia: a randomized double blind controlled evaluation.
    Vanacker B; Van Aken H
    Acta Anaesthesiol Belg; 1990; 41(1):9-12. PubMed ID: 2193475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular responses to the stimulation of alpha-1 and alpha-2 adrenoceptors in the conscious dog.
    Woodman OL; Vatner SF
    J Pharmacol Exp Ther; 1986 Apr; 237(1):86-91. PubMed ID: 2870177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ritanserin and serotonergic mechanisms in blood pressure and fluid regulation in sheep.
    Nelson M; Coghlan JP; Denton DA; Tresham JJ; Whitworth JA; Scoggins BA
    Clin Exp Pharmacol Physiol; 1987 Jul; 14(7):555-63. PubMed ID: 3124998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serotonin and the heart: effects of ketanserin on myocardial function, heart rate, and arrhythmias.
    Saman S; Thandroyen F; Opie LH
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S70-5. PubMed ID: 2412064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the cardiovascular effects of co-derocrine (Hydergine).
    Clark BJ; Bucher T; Waite R
    J Pharmacol; 1985; 16 Suppl 3():101-11. PubMed ID: 2869189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antihypertensive and metabolic effects of ketanserin in diabetic patients with mild hypertension.
    Beretta-Piccoli C; Salvadé G; Bachmann C; Riesen W; Zuppinger K
    J Hum Hypertens; 1988 Aug; 2(2):103-10. PubMed ID: 3072419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of ketanserin on phenylephrine-dependent changes in splanchnic hemodynamics and systemic blood pressure in healthy subjects.
    Gasic S; Eichler HG; Korn A
    J Cardiovasc Pharmacol; 1985; 7(2):219-23. PubMed ID: 2581071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: implications for atypical antipsychotics.
    Gilles M; Wilke A; Kopf D; Nonell A; Lehnert H; Deuschle M
    Psychosom Med; 2005; 67(5):748-51. PubMed ID: 16204433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ketanserin, hypertension, and chronic alcoholism: double-blind study in forty patients.
    de Lorenzo A; Ceccanti M; Assogna G; Romeo M; Cavaleri G; Attilia ML
    Int J Clin Pharmacol Res; 1988; 8(5):321-5. PubMed ID: 3068159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of ketanserin, methysergide and LY 53857 on sympathetic nerve activity.
    Ramage AG
    Eur J Pharmacol; 1985 Jul; 113(3):295-303. PubMed ID: 2931285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade.
    Leenen FH; Davies RA; Fourney A
    Clin Pharmacol Ther; 1998 Nov; 64(5):522-35. PubMed ID: 9834044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Responses of the systemic circulation and of the renin-angiotensin-aldosterone system to ketanserin at rest and exercise in normal man.
    Fagard R; Cattaert A; Lijnen P; Staessen J; Vanhees L; Moerman E; Amery A
    Clin Sci (Lond); 1984 Jan; 66(1):17-25. PubMed ID: 6690191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular effects in the rat of ketanserin, a novel 5-hydroxytryptamine receptor blocking agent.
    Persson B; Hedner T; Henning M
    J Pharm Pharmacol; 1982 Jul; 34(7):442-5. PubMed ID: 6126541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency.
    Wenting GJ; Woittiez AJ; Man in't Veld AJ; Schalekamp MA
    Hypertension; 1984; 6(1):100-9. PubMed ID: 6319278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in normal man.
    Zoccali C; Zabludowski JR; Isles CG; Murray GD; Inglis GC; Robertson JI; Fraser R; Ball SG
    Br J Clin Pharmacol; 1983 Sep; 16(3):305-11. PubMed ID: 6626423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive mode of action of ketanserin.
    Robertson JI; Stott DJ; Ball SG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S45-7. PubMed ID: 2446069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.